Sanofi Rilzabrutinib Wins Japan Orphan Status
Paris, March 2, 2026 Sanofi announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug...
immunology
Advertisement
TREMFYA Sustains UC Remission Through 3 Years
STOCKHOLM, Sweden, Feb. 21, 2026 — Johnson & Johnson announced new long-term findings from the QUASAR long-term extension study...
Hoth Secures Patent Allowance for Allergy RNA Therapy
NEW YORK, Feb. 12, 2026 — Hoth Therapeutics announced that the U.S. Patent and Trademark Office has issued a...
KalVista Showcases EKTERLY Data at AAAAI 2026 Meet
FRAMINGHAM, Mass. & SALISBURY, England, Feb. 12, 2026 — KalVista Pharmaceuticals announced the presentation of new clinical and real-world...
Third Arc Bio Secures $52M to Advance Antibody Pipeline
SPRING HOUSE, Pa., Feb. 4, 2026 — Clinical-stage biotechnology company Third Arc Bio announced the closing of a $52...
Advertisements
OSE Expands Lusvertikimab Into Pouchitis and HS
Nantes, France | January 29, 2026 — OSE Immunotherapeutics announced the strategic selection of chronic pouchitis and hidradenitis suppurativa...
GSK Acquires RAPT in $2.2B Bet on Food Allergy Therapy
London, United Kingdom, January 21, 2026 — GSK has announced a $2.2 billion acquisition of RAPT Therapeutics, securing global...
Parse and Graph Launch Massive AI-Driven Immune Atlas
Seattle and Vienna, January 20, 2026 — Parse Biosciences and Graph Therapeutics have announced a strategic partnership to create...
Lilly to Acquire Ventyx to Expand Oral Inflammation Therapies
INDIANAPOLIS | January 7, 2026 — Eli Lilly and Company has announced an agreement to acquire Ventyx Biosciences, a...
Apogee Shows Durable Phase 1b Asthma Data for IL-13 Biologic
SAN FRANCISCO & BOSTON | January 6, 2026 — Apogee Therapeutics has reported positive interim results from a Phase...
Advertisement
